維基百科

荻野周史

荻野周史（日語：荻野 周史／おぎの しゅうじ Ogino Shūji，1968年4月24日—），主要從事病理學，流行病學和分子病理流行病學研究。目前在哈佛醫學院，布萊根婦女醫院和丹娜法伯癌症研究院及哈佛陳曾熙公共衛生學院擔任教授。荻野首次提出分子病理流行病學（英語：Molecular pathological epidemiology）（MPE）這一學科概念，該學科是分子病理學和流行病學的交叉學科。

生平

於1993年獲得東京大學醫學院學士學位，於1994-1995年在沖繩美國海軍醫院實習，隨後赴美，並分別在卓克索大學阿勒格尼總醫院（1995-1997）及凱斯西儲大學/克利夫蘭大學醫院（1997-1999）完成病理解剖和臨床病理住院醫師培訓，1999-2000年在賓夕法尼亞大學醫學中心進行分子病理學研究。2001年獲得東京大學研究院醫學系博士學位後繼續在該中心從事博士後研究，2001-2004在丹娜法伯癌症研究院，布萊根婦女醫院和哈佛醫學院擔任病理學講師，2004年晉升為助理教授，2008年晉升為副教授，2015年晉升為丹娜法伯癌症研究院教授。繼2011年在哈佛陳曾熙公共衛生學院獲得流行病學碩士學位後，被任命為該學院的流行病學副教授，並2015年晉升為教授。

研究領域和成果

荻野於2010年首次提出 「分子病理流行病學（MPE）」[1]這一概念。他認為將分子病理學研究帶入流行病學研究的框架是一個獨特的研究領域。此後，MPE這一概念被廣泛採納[2][3][4][5][6][7][8][9][10][11][12] ，並且成為美國癌症研究協會（AACR）[13] ，流行病學研究協會（SER）[14]和美國預防腫瘤學會（ASPO）[15]等國際會議的專題。MPE是採用分子病理學流行病學的方法從分子、個體和群體的水平進行病因學的研究。通過對現有的流行病學研究中組織樣本和數據的研究分析，荻野發表了大量的文章論述危險因素（如環境、飲食、生活方式和遺傳因素等）的暴露和疾病的分子病理學特徵之間的相互關係（例如，攜帶PIK3CA突變基因的結直腸癌），其中很多發現 [16][17][18][19][20][21][22][23]以及闡述 MPE的概念[24][25][26][27][28][29][30][31] 的文章都發表在該領域具有影響力的雜誌上。通過MPE的研究方法荻野發現了阿士匹靈可以增加攜帶PIK3CA基因突變的結直腸癌患者的生存期 [32] ，內鏡篩查有助於降低結腸癌的發病率和死亡率，以及結腸鏡檢5年內發生的大腸癌與其CIMP（CpG 島甲基化表型）和MSI （微衛星不穩定性）有關[33]。Ogino 於2013年舉辦首屆分子病理流行病學（MPE）會議，並於2014年12月4-5號在波士頓召開第二次會議[34][35]。

荻野採用MPE的研究方法提出在大腸癌研究模型從兩段式結腸模型（近段和遠段結腸）[36] [37] [38] [39]到大腸連續模型[40]的轉變。該假設是通過對 1400多例大腸癌病例分析，得出不同部位的結腸癌與其微衛星不穩定（MSI），CpG島甲基化表型（CIMP）和BRAF突變頻率呈線性關係[41] ，這一大腸連續模型已得到支持 [42][43]。 此外，荻野還提出了一些新的研究模式，包括「GWAS-MPE」 [44] ，「 獨特腫瘤原則」[45] ，「獨特疾病原則」[46] ，「病因場效應模型」 [47] （即多種治病因素包括飲食、生活方式、環境、微生物、激素和基因等及其相互作用下的形成腫瘤易感組織微環境，致使腫瘤形成、演化和進展）以及「生命歷程流行病學 - MPE模型」[48] ，所有這些模型都與MPE領域相關。

榮譽

  • 2004年，分子病理學協會（AMP），總裁獎
  • 2011年，美國加拿大病理學協會，拉姆茲•科特蘭青年研究獎
  • 2012年，分子病理學協會（AMP），功勳獎
  • 2014年，湯森路透 [49]， 最具影響力的科學家
  • 2014年，美國臨床調查協會（ASCI），委員
  • 2014年，美國實驗生物學會聯合會傑出科學獎委員會[50]，委員

外部連結

參考文獻

  1. ^ Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-367.
  2. ^ Curtin K, Slattery ML, Samowitz WS (2011). "CpG island methylation in colorectal cancer: past, present and future". Pathology Research International 2011: 902674. doi:10.4061/2011/902674. PMC 3090226. PMID 21559209.
  3. ^ Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012). "Cancer classification using the Immunoscore: a worldwide task force". Journal of Translational Medicine 10: 205. doi:10.1186/1479-5876-10-205. PMC 3554496. PMID 23034130.
  4. ^ Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R, Iacopetta B (August 2012). "Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X". Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc 25 (8): 1055–68. doi:10.1038/modpathol.2012.62. PMID 22522846.
  5. ^ Koshiol J, Lin SW (July 2012). "Can tissue-based immune markers be used for studying the natural history of cancer?". Annals of Epidemiology 22 (7): 520–30. doi:10.1016/j.annepidem.2012.03.001. PMC 3596808. PMID 22481034.
  6. ^ Fini L, Grizzi F, Laghi L (2012). Ettarh R, ed. Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression. InTech. pp. 323–40. ISBN 9789535100621.
  7. ^ Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M (November 2012). "Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers". Clinical Cancer Research 18 (22): 6169–77. doi:10.1158/1078-0432.CCR-11-3265. PMC 3500422. PMID 23014527.
  8. ^ Spitz MR, Caporaso NE, Sellers TA (December 2012). "Integrative cancer epidemiology--the next generation". Cancer Discovery 2 (12): 1087–90. doi:10.1158/2159-8290.CD-12-0424. PMC 3531829. PMID 23230187.
  9. ^ Shanmuganathan R, Basheer NB, Amirthalingam L, Muthukumar H, Kaliaperumal R, Shanmugam K (January 2013). "Conventional and nanotechniques for DNA methylation profiling". The Journal of Molecular Diagnostics : JMD 15 (1): 17–26. doi:10.1016/j.jmoldx.2012.06.007. PMID 23127612.
  10. ^ Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M (October 2013). "The CpG island methylator phenotype: what's in a name?". Cancer Research 73 (19): 5858–68. doi:10.1158/0008-5472.CAN-12-4306. PMID 23801749.
  11. ^ Hagland HR, Søreide K (March 2014). "Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways". Cancer Letters. doi:10.1016/j.canlet.2014.02.026. PMID 24614287.
  12. ^ Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R (May 2014). "Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention". World Journal of Gastroenterology : WJG 20 (20): 6055–72. doi:10.3748/wjg.v20.i20.6055. PMC 4033445. PMID 24876728.
  13. ^ Ogino S. Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Cancer Prev Res (Phila). 2013;6(11 suppl):CN06-1.
  14. ^ Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178(9):1350-4.
  15. ^ Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and Opportunities in International Molecular Cancer Prevention Research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2613-7. doi: 10.1158/1055-9965.EPI-14-0848. Epub 2014 Oct 2.
  16. ^ Chan AT, Ogino S, Fuchs CS. Aspirin use and risk of colorectal cancer according to cyclooxygenase-2 expression. N Engl J Med 2007;356:2131-42.
  17. ^ Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
  18. ^ Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-1694. PMCID:PMC3087286109
  19. ^ Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012;487:500-504. PMCID:PMC3711467
  20. ^ Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and colorectal cancer incidence risk according to BRAF mutation status. JAMA 2013;309:2563-2571.
  21. ^ Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson III AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, for the Alliance for Clinical Trials in Oncology. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013;105:1789-1798.
  22. ^ Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013;493:106-110. PMCID:PMC3536889
  23. ^ Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, Markowitz SD, Chan AT. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
  24. ^ Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology – integrated analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011:8:711-719.
  25. ^ Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am J Epidemiol 2012;176:659-667.
  26. ^ Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability – Molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 2012;41:1072-1074.
  27. ^ Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-628.
  28. ^ Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E (April 2013). "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease". Modern Pathology 26(4): 465–84.
  29. ^ Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013;310:2147-2148.
  30. ^ Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33:2949-2955.
  31. ^ Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O』Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014;109(8):1205-1214.
  32. ^ Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-1606.
  33. ^ Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.
  34. ^ The Ogino MPE lab ( http://ogino-mpe-lab.dana-farber.org （頁面存檔備份，存於互聯網檔案館） )
  35. ^ Ogino S, Campbell PT, Nishihara R, Phipps AI, Beck AH, Sherman ME, Chan AT, Troester MA, Bass AJ, Fitzgerald KC, Irizarry RA, Kelsey KT, Nan H, Peters U, Poole EM, Qian ZR, Tamimi RM, Tchetgen Tchetgen EJ, Tworoger SS, Zhang X, Giovannucci EL, van den Brandt PA, Rosner BA, Wang M, Chatterjee N, Begg CB.，
  36. ^ Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403–8.
  37. ^ Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.
  38. ^ Carethers JM. One colon lumen but two organs. Gastroenterology. 2011;141:411–2.
  39. ^ Albuquerque C, Bakker ER, van Veelen W, et al. Colorectal cancers choosing sides. Biochim Biophys Acta. 2011;1816:219–31.
  40. ^ Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Colorectal cancer: a tale of two sides or a continuum? Gut. 2012 Jun;61(6):794-7.
  41. ^ Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854. PMCID:PMC3345105
  42. ^ Jess P, Hansen IO, Gamborg M, Jess T; Danish Colorectal Cancer Group. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013 May 28;3(5).
  43. ^ Papagiorgis P. Colorectal cancer: dichotomous or continuum model? Perhaps, a combination of both. Gut. 2013 Oct;62(10):1519-20.
  44. ^ Ogino S, Chan AT, Fuchs CS, Giovannucci E. Gut. 2011 Mar;60(3):397-411. doi: 10.1136/gut.2010.217182. Epub 2010 Oct 29. Review. PMID 21036793 Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.
  45. ^ Ogino S, Fuchs CS, Giovannucci E. Expert Rev Mol Diagn. 2012 Jul;12(6):621-8. doi: 10.1586/erm.12.46. Review. PMID 22845482 How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
  46. ^ Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Mod Pathol. 2013 Apr;26(4):465-84. doi: 10.1038/modpathol.2012.214. Epub 2013 Jan 11. Review. PMID 23307060 Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.
  47. ^ Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28(1):14-29. doi: 10.1038/modpathol.2014.81. Epub 2014 Jun 13. PMID 24925058.
  48. ^ Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 2015;48:116-119.
  49. ^ The world’s Most Influential Minds:2014 (存档副本. [2014-10-09]. （原始內容存檔於2014-10-07）. ) Thomson Reuter. Retrieved September 5, 2014.
  50. ^ http://www.faseb.org/About-FASEB/Who-We-Are/Governance/Board-Ordinary-Committees.aspx （頁面存檔備份，存於互聯網檔案館） Retrieved September 15, 2014.
取自 "https://zh.wikipedia.org/w/index.php?title=荻野周史&oldid=84344056"